UNSPSC 51386610: Hydrocortisone/pramoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386610 Hydrocortisone/pramoxine, a Commodity code, nominally describes a specific topical corticosteroid-anesthetic combination product, but recent state and local procurement activity under this code shows substantial mismatch. The three most recent opportunities posted under the code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmaceutical prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). The code does not align with the actual scope of work being procured, suggesting indexing or tagging inconsistency at the source level. State and local issuing bodies using this code include county health departments, state health agencies, and multistate cooperative purchasing consortia; no repeat buyers appear in the recent record beyond the single Seminole County opportunity.

Activity appears concentrated in Texas, Minnesota, and Florida based on the three recent opportunities. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, under a two-year term with one-year renewal option. The Texas Health and Human Services Commission posted an RFI (HHS0017013, response due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing vehicle, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities, with contract awards effective July 1, 2026. Vendors for MMCAP must maintain relationships with at least two of three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements. Given the disconnect between the code's stated scope and recent solicitation content, this code warrants close attention to ensure proper UNSPSC alignment before pursuing opportunities tagged under it.